NATICK, Mass. - Allurion Technologies, Inc. (NYSE: ALUR), a company focused on obesity treatment solutions, has expanded its ...

The U.S. Patent and Trademark Office granted Patent No. 12,209,677, which pertains to advancements in Allurion's proprietary Balloon technology, particularly improving the precision of the valve ...

James Manning / PA Images via Getty Images Allurion Technologies said it planned to test its gastric balloon with the key ingredient in popular weight-loss drugs to see if the combination improves ...

Allurion Technologies (ALUR) announced its intention to initiate a clinical study on the combination of the Allurion Program with GLP-1 ...

If you can’t beat them then join them. In a bid to combat weakening financial performance, Allurion has revealed plans to initiate a clinical study evaluating its weight loss programme in ...

1 In contrast, in previous studies, patients treated with the Allurion Balloon in combination with the Allurion Virtual Care Suite have demonstrated strong patient outcomes in which patients lose ...

Shares of Allurion (NYSE:ALUR) soared 70% in post-market trading Thursday after ending the regular session 21% higher on news the company plans to conduct a clinical study of its gastric balloon ...

Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced its intention to initiate a clinical study on the combination of the ...

Allurion (NYSE: ALUR) surged 83% premarket after revealing a clinical study combining its gastric balloon product with GLP-1 drugs, showing muscle mass maintenance. Stardust Power (NASDAQ ...